Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

First Posted Date
2022-06-03
Last Posted Date
2024-10-10
Lead Sponsor
Taofeek Owonikoko
Target Recruit Count
50
Registration Number
NCT05403723
Locations
🇺🇸

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer

Phase 2
Recruiting
Conditions
Vulvar Cancer
Interventions
Drug: Bleomycin
Drug: Carboplatin
First Posted Date
2022-05-27
Last Posted Date
2022-05-27
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Target Recruit Count
92
Registration Number
NCT05395962
Locations
🇮🇹

IRCCS- Azienda Ospedaliera-Universitaria di Bologna, Bologna, Bo, Italy

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC

First Posted Date
2022-05-27
Last Posted Date
2022-05-27
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Target Recruit Count
30
Registration Number
NCT05394415
Locations
🇨🇳

Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

First Posted Date
2022-05-24
Last Posted Date
2024-06-06
Lead Sponsor
Heath Skinner
Target Recruit Count
150
Registration Number
NCT05388773
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

First Posted Date
2022-05-23
Last Posted Date
2024-12-13
Lead Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Target Recruit Count
65
Registration Number
NCT05386888
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

First Posted Date
2022-05-20
Last Posted Date
2024-02-20
Lead Sponsor
Fundación GECP
Target Recruit Count
85
Registration Number
NCT05384015
Locations
🇪🇸

Hospital General Universitario de Valencia, Valencia, Spain

🇪🇸

ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain

and more 15 locations

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

First Posted Date
2022-05-19
Last Posted Date
2024-10-23
Lead Sponsor
BeiGene
Target Recruit Count
210
Registration Number
NCT05381909
Locations
🇦🇺

Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia

🇦🇺

Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

🇺🇸

Banner Md Anderson Cancer Center, Gilbert, Arizona, United States

and more 19 locations

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

First Posted Date
2022-05-19
Last Posted Date
2024-12-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
540
Registration Number
NCT05382299
Locations
🇺🇸

Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway, Lecanto, Florida, United States

🇺🇸

Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, United States

🇺🇸

Florida Cancer Specialists,681 4th Avenue North, Naples, Florida, United States

and more 512 locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

First Posted Date
2022-05-19
Last Posted Date
2024-12-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
440
Registration Number
NCT05382286
Locations
🇺🇸

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

🇺🇸

Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, United States

and more 501 locations

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

First Posted Date
2022-05-17
Last Posted Date
2024-02-21
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
43
Registration Number
NCT05377658
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy